Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart).

BMJ open·2026
Same author

Chronic histiocytic intervillositis: Insights into immunopathogenesis and prospective treatments.

Journal of reproductive immunology·2026
Same author

Single-cell transcriptomics identifies regulatory T cell heterogeneity in gestational diabetes mellitus.

Communications medicine·2026
Same author

Perfusion microbioreactor for CAR-Treg manufacturing.

iScience·2026
Same author

Phase I trial of autologous regulatory T cells for immune aplastic anemia.

Haematologica·2026
Same author

Corrigendum to "Chronic exposure to l-BMAA cyanotoxin induces cytoplasmic TDP-43 accumulation and glial activation, reproducing an amyotrophic lateral sclerosis-like phenotype in mice" [Biomed. Pharmacother. 167 (2023) 115503].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Dendritic cell subsets in alopecia areata: focus on plasmacytoid dendritic cells and Langerhans cells in immune imbalance and therapeutic implications.

Expert review of clinical immunology·2026
Same journal

The role of immunosenescence and chronic medical conditions on the immune response to respiratory syncytial virus in older individuals.

Expert review of clinical immunology·2026
Same journal

Flow cytometry-based basophil and mast cell activation tests for IgE-mediated food and drug allergy: have we crossed the Rubicon?

Expert review of clinical immunology·2026
Same journal

An update on the pharmacotherapy of ANCA-associated vasculitis.

Expert review of clinical immunology·2026
Same journal

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.

Expert review of clinical immunology·2026
Same journal

Why is the antigen uptake receptor DEC205 (CD205) of interest?

Expert review of clinical immunology·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

CD4+CD25+ regulatory T-cell therapy.

Shuiping Jiang1, Robert I Lechler, Giovanna Lombardi

  • 1Immunoregulation Laboratory, Department of Nephrology and Transplantation, King's College, Guy's Hospital, London SE1 9RT, UK. shuiping.jiang@kcl.ac.uk

Expert Review of Clinical Immunology
|May 19, 2010
PubMed
Summary
This summary is machine-generated.

Naturally occurring CD4(+)CD25(+) regulatory T cells (Tregs) are crucial for controlling autoimmunity. Adoptive transfer of these cells shows promise for treating autoimmune diseases and improving transplant tolerance, paving the way for personalized cell therapies.

More Related Videos

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Related Experiment Videos

Last Updated: Jun 13, 2026

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Area of Science:

  • Immunology
  • Cell Therapy
  • Autoimmunity

Background:

  • CD4(+)CD25(+) regulatory T cells (Tregs), identified by the transcription factor FoxP3, are vital for immune homeostasis.
  • Research indicates Tregs play a significant role in preventing and managing autoimmune conditions.
  • Their potential in inducing tolerance in transplantation is increasingly recognized.

Purpose of the Study:

  • To review recent advancements in the therapeutic application of CD4(+)CD25(+) Tregs.
  • To highlight the potential of Tregs in personalized medicine and adoptive cell therapy.
  • To discuss the progress made in utilizing Tregs for treating autoimmune and allergic diseases.

Main Methods:

  • Review of existing literature and experimental findings in animal models.
  • Analysis of studies focusing on the adoptive transfer of CD4(+)CD25(+) Tregs.
  • Examination of research on Treg-based therapies for autoimmune diseases and transplantation.

Main Results:

  • CD4(+)CD25(+) Tregs are established regulators of autoimmunity.
  • Adoptive transfer of Tregs has demonstrated efficacy in curing autoimmune and allergic diseases in animal models.
  • Tregs show potential in inducing donor-specific tolerance in transplantation settings.

Conclusions:

  • Customer-tailored CD4(+)CD25(+) Tregs represent a promising avenue for adoptive cell therapy.
  • These cells hold significant potential for individualized medicine, particularly in managing autoimmune disorders and enhancing transplant outcomes.
  • Continued research is advancing the clinical application of Tregs for therapeutic purposes.